NCT00505531终止不适用
Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Tramadol ER reduces VAS for patients with OIH
研究概览
简要总结
The Massachusetts General Hospital Center for Translational Pain Research is conducting a research study to see if Ultram ER, an FDA-approved pain medication, would be helpful in providing pain relief in subjects whose chronic pain is not well controlled on narcotic pain medicine.
详细描述
The study consists of 6 visits over 6 weeks. Study testing includes: physical exam, urine testing, questionnaires and non-invasive (no needles) nerve testing using cold/heat sensations. Compensation and some parking reimbursement provided.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject will be between ages 18 to 65 years in all three groups.
- •Subject has NOT been on Tramadol or Tramadol ER for at least one month.
- •Subject has NOT been on tricyclic antidepressants, serotonin, norepinephrine, or mixed serotonin/norepinephrine reuptake inhibitors (SSRI/SNRI), or muscle relaxant with potential action as an SSRI or SNRI (e.g., Flexeril) for at least one month. Subject has not been on monoamine oxidase inhibitors in the past 14 days.
- •Subjects should have had a stable pain condition (e.g., axial low back pain as listed below in item # 5-7) for at least three months. This requirement is set in order to avoid clinical uncertainty from an unstable pain condition and to minimize the study variation.
- •Axial low back pain refers to pain conditions resulting from myofascial disorder, lumbar facet joint disease, discogenic disease, and postlaminectomy syndrome. Patients with neurological signs (weakness or numbness) will not be included in the study because of potential confounding effects on the QST assessment of pain threshold and pain tolerance.
- •Headaches refer to migraine, tension, or cluster headache, cervicogenic pain (e.g., facet joint disease, myofascial pain), and trigeminal neuralgia. However, patients with neurological diseases including multiple sclerosis, amyotrophic lateral sclerosis, and stroke will not be included due to possible neurological deficits that may confound the QST assessment.
- •Abdominal and pelvic pain refers to pain from abdominal and/or pelvic organs (e.g., chronic pancreatitis, endometriosis).
- •Subject is willing to have his/her opioid dose tapered.
- •Female subjects of childbearing potential must have a negative urine pregnancy test at the initial visit.
排除标准
- •Subject has sensory deficits at the sites of QST. Sensory deficits refer to such changes resulting from neurological diseases or medical conditions causing peripheral polyneuropathy and sensory changes, which include but are not limited to diabetes, alcoholic neuropathy, AIDS neuropathy, thyroid disease, severe liver or kidney disorders.
- •Subject has scar tissue, infection, or acute injury at the sites of QST.
- •Subject has had interventional procedures that may alter the results of QST. Such procedures include neuroablation (chemical or electrothermal) at any time, neuraxial (e.g., epidural) or local anesthetic block within the last eight weeks, and lumbar sympathetic or hypogastric block within the last six months. We consider eight weeks and six months as the minimal time period that must have elapsed after neuraxial injection and lumbar sympathetic block, respectively, in order to minimize the possible influence from a previous interventional procedure.
- •Subject has a pending litigation related to his/her chronic pain condition.
- •Subject has a history of or current seizure disorder.
- •Subject has a history of severe allergic reaction to Tramadol ER or other opioid medications.
- •Subject has a major psychiatric disorder (major depression; bipolar disorder; schizophrenia; anxiety disorder; psychotic disorders; eating disorders; alcohol or drug dependence; attention deficit hyperactivity disorder); subject with any known history of such conditions also will be excluded.
- •Subject has severe renal impairment or severe hepatic impairment.
- •Subject is using illicit drugs detected through the urine toxicology screen.
- •Subject is pregnant or lactating.
研究组 & 干预措施
Placebo
Diphenhydramine capsules Weeks 1-6- 25 mg/day
干预措施: Benadryl (Drug)
Tramadol ER- 200mg
Tramadol Extended Release capsules Weeks 1 & 6- 100 mg/day Weeks 2-5- 200 mg/day
干预措施: Tramadol Extended Release Oral Capsule (Drug)
Tramadol ER- 300mg
Tramadol Extended Release capsules Weeks 1 & 7- 100 mg/day Weeks 2 & 6- 200 mg/day Weeks 3-5- 300 mg/day
干预措施: Tramadol Extended Release Oral Capsule (Drug)
结局指标
主要结局
Tramadol ER reduces VAS for patients with OIH
时间窗: 6 weeks
VAS will be recorded at each visit and then analyzed
次要结局
未报告次要终点
研究者
Jianren Mao, MD, PhD
Principal Investigator
Massachusetts General Hospital
研究点 (1)
Loading locations...
相似试验
已完成
4 期
The Back Pain Consortium Research Program StudyChronic Low-back PainNCT04870957University of Michigan494
招募中
不适用
Plantar Fasciitis Randomized Clinical Control TrialPlantar FascitisNCT03231150University of Pennsylvania62
撤回
不适用
AlloGen-LI Treatment of Spinal StenosisLow Back PainNCT02932020University of Southern California
已完成
不适用
Transversus Abdominis Plane Block and Inguinal Hernia RepairAbdominal Wall MusclesRegional AnesthesiaPostoperative PainInguinal HerniaNCT02030223Papacharalampous Panagiota59
撤回
不适用
IVs With Buzzy in Chronic Pain PatientsChronic PainAcute PainNCT05555173Steward St. Elizabeth's Medical Center of Boston, Inc.10